GID BIO completes enrollment for randomized double-blinded pivotal Phase III cell therapy study for treatment of knee osteoarthritis

Posted on by

LOUISVILLE, Colo., Feb. 12, 2024 /PRNewswire/ — GID BIO, Inc. completed enrollment for the first of two pivotal Phase III studies to investigate the use of your own stromal vascular fraction (SVF) cells to treat osteoarthritis of the knee. The clinical study involves a cellular…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.